We also used CRISPR-Cas9 gene editing to disrupt the +58 enhancer of the γ-globin repressor BCL11A in HBB−/− cells, using a previously validated sgRNA19, an approach granted PRIME designation for TDT and SCD, with planned regulatory submission this year. This evidence concerns the gene BCL11A and Schnyder corneal dystrophy.